Pharmacy Services

Q4-2019 Pharmacy & Infusion Services Update – A landmark transaction between Diplomat and Optum Rx defined the final quarter of 2019, resulting in the exit of the largest independent specialty pharmacy in the U.S.

Diplomat and BioScrip Deals Illustrate Changing Industries – Micheal Patton and Bill Bolding share some of their insight on specialty pharmacies and infusion providers with Radar on Specialty Pharmacy.

Pharmaceutical Services: Spotlight on Tech-Enabled Clinical Development – The shift of development dollars to biologics and medicines for smaller, targeted populations is creating opportunities for outsourcing partners with the expertise as well as flexibility to work with midsize and emerging biopharmaceutical companies.

Q3-2019 Pharmacy Infusion Services Update – Deals continue to occur in both traditional areas of pharmacy services such as retail and LTC, as well as new, emerging verticals such as health system specialty pharmacy services.

Q2-2019 Pharmacy Infusion Services Update – Transaction activity occurred within multiple sub-sectors of pharmacy services including LTC, infusion therapy, and specialty. Given the historical and future growth trajectory of the space, consolidation and investment activity is expected to continue for the foreseeable future.

Cannabis, Hemp Producers Targeted in May Health-Care Deals – The health-care industry is getting into the weed business.

Consolidation in Outsourced Pharmaceutical Services– Contract Research Organizations (CROs) and Contract Development & Manufacturing Organizations (CDMOs) are utilizing strategic mergers, acquisitions, and private equity partnerships to capitalize on tailwinds in the outsourced pharmaceutical services sector.

Health-Care Deals Steady, Strong Through First Third of 2019– Consistency is the name of the game for health-care industry transactions in 2019 so far.

INSIGHT: Health Care M&A Transactions on Pace to Set Record in 2019– March madness is over for college basketball fans, but it’s just the beginning of a fast-paced year for health-care M&A activity.

Q1-2019 Pharmacy Services Update – Private equity investment and M&A continued to reshape the pharmacy and infusion services sectors in the first quarter of 2019. Despite a recent wave of vertical integration between payors, PBMs and providers in the latter half of 2018, large-scale acquisitions have and will continue to occur as stakeholders expand their core competencies.

BioScrip, Option Care Will Join Forces Within Infusion Market – Micheal Patton and Bill Bolding share some of their insight on the specialty pharmacy space with Radar on Specialty Pharmacy.

Healthcare Services M&A: A 2018 Recap and Expectations for 2019 – Episode 8 of Provident’s Healthcare Dealcast

  • “After working with Provident on several transactions, it is evident that their extensive industry knowledge and deal expertise prove to be invaluable to their clients.”

  • “Provident listened to our story, confirmed that our business was valuable and made us feel like this was the only transaction important to them.”

  • “A lot of investment bankers were interviewed, Provident was chosen. Provident delivered. My clients could not be happier.”

  • “Provident’s depth of experience and practical business savvy was demonstrated in their ability to cut through what sometimes looked like impasse.”

  • ”I have a tremendous amount of appreciation and gratitude to the Provident team for their hard work and diligence throughout this process. Each and every member of the Provident team is excellent at their jobs and it has been a pleasure working with such a professional team. Provident has provided outstanding guidance and counsel, and this deal could never have gotten done without Provident’s leadership.”

  • “We would not have been successful navigating the process without Provident’s hard work and active participation. They exceeded our expectations and we would highly recommend them to any health care company seeking a knowledgeable and engaged investment banking firm.”

  • “While the decision to sell our business was a difficult one, Provident vigilantly represented and protected our best interests throughout the transaction.  Provident was the right choice for Cascade and I would recommend their services to anyone.”